Skip to main content
. 2023 Aug 16;15(8):2149. doi: 10.3390/pharmaceutics15082149

Figure 1.

Figure 1

Identification and homing of Br-MSCs (A–I). (A) Br-MSCs cells 7th of culture, Scale bar 20 µm, (B) homing of Br-MSCs in rat kidney tissue of Br-MSCs treated group 3rd post-transplantation assayed by PKH-26, Scale bar 100 µm, (C) homing of Br-MSCs in rat kidney tissue of Br-MSCs + EXOs treated group 3rd post-transplantation assayed by PKH-26, Scale bar 100 µm, (D) flow cytometry of CD105 positive Br-MSCs, (E) flow cytometry of CD90 positive Br-MSCs, (F) flow cytometry of CD73 positive Br-MSCs, (G) flow cytometry of CD34 negative Br-MSCs, (H) flow cytometry of CD45 negative Br-MSCs, (I) flow cytometry of HLA-DR negative Br-MSCs, and (J) % of the mean fluorescent intensity for positive and negative cell population for CD105, CD90, CD73, CD34, CD45, and HLA-DR.